Trial · NCT07108504
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT07108504, Phase 2, Not yet recruiting, Shanghai Zhongshan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer. Trials, record NCT07108504. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07108504
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- NCT number
- NCT07108504
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Shanghai Zhongshan Hospital
- Conditions
- Pancreatic Cancer, Chemotherapy Effect
- Interventions
- Gemcitabine, LM-302
- First posted
- 2025-08-07
- Last updated
- 2025-08-07
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) per RECIST 1.1 | From baseline until disease progression or study completion (up to 24 months). | The proportion of participants with CLDN18.2-positive unresectable locally advanced or metastatic pancreatic adenocarcinoma achieving a best overall response of complete response (CR) or partial response (PR) as assessed by the investigator according to RECIST 1.1 criteria. |
| Secondary | Duration of Response (DOR) per RECIST 1.1 | From first response until progression/death (up to 24 months). | The time from first documented objective response (CR or PR) until disease progression or death, whichever occurs first, as assessed by RECIST 1.1. |
| Secondary | Disease Control Rate (DCR) per RECIST 1.1 | From baseline until confirmed SD/response (up to 24 months). | The proportion of participants achieving CR, PR, or stable disease (SD) lasting ≥16 weeks, as assessed by RECIST 1.1. |
| Secondary | Progression-Free Survival (PFS) per RECIST 1.1 | From first dose of study treatment until disease progression (per RECIST 1.1) or death from any cause, assessed up to 24 months. | Progression-Free Survival (PFS) is defined as the time from the first dose of study treatment (LM-302 + Gemcitabine) to the first occurrence of disease progression (per RECIST 1.1) or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | From first dose of study treatment until death from any cause or the end of follow-up, whichever occurs first, assessed up to 36 months. | Overall Survival (OS) is defined as the time from the first dose of study treatment (LM-302 + Gemcitabine) to death from any cause. |
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From first dose until 30 days after last dose (up to 24 months). | Frequency and severity of adverse events (AEs), serious AEs (SAEs), and laboratory abnormalities graded by CTCAE v5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07108504
GET https://conductscience.org/api/trials/v1/NCT07108504/registered